InvestorsHub Logo
Followers 1321
Posts 26908
Boards Moderated 6
Alias Born 12/10/2012

Re: None

Friday, 04/29/2022 7:01:25 AM

Friday, April 29, 2022 7:01:25 AM

Post# of 1860
$QLIS: IPO Regiistration AMended




https://docoh.com/filing/1871181/0001493152-22-010489/QLIS-S1A


Presently, the Company is in the process of preparing the documents necessary to submit an application to the FDA for clearance of our planned device. We plan on also filing a provisional patent for the changes and new development of our device over our previous licensed device from LCMD, The Company has an accumulated deficit of $2,704,772. It is anticipated that the total expected financial outlay to complete the development and FDA application is approximately $250,000, combined with operating expenses the Company may not be able to have enough cash flow to support the Company’s daily operations resulting in an opinion by the auditors of the Company continuing as a going concern.



We anticipate that our SOLACE device will be cleared by the FDA via the 510k process and that it will be deemed to be substantially equivalent to the identified predicate device called the Bebe device, The Bebe device was originally cleared by the FDA in 2014 by the Marchito Entities and subsequently sold to LCMD via an Asset Purchase Agreement and an Intellectual Property License Agreement. The Bebe device is indicated for use in the treatment of selected medical conditions such as pain relief, muscle spasms, and joint contractures, but not for the treatment of malignancies.








GO $QLIS